Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform
Despite the well-recognized clinical success of therapeutic proteins, especially antibodies, their inability to penetrate the cell membrane restricts them to secretory extracellular or membrane-associated targets. Developing a direct cytosolic protein delivery system would offer unique opportunities for intracellular target-related therapeutic proteins. Here, we generated a supercharged polypeptide (SCP) with high cellular uptake efficiency, endosomal escape ability, and good biosafety and developed an SCP with an unnatural amino acid containing the phenylboronic acid (PBA) group, called PBA-SCP. PBA-SCP is capable of potently delivering proteins with various isoelectric points and molecular sizes into the cytosol of living cells without affecting their bioactivities. Importantly, cytosolically delivered antibodies remain functional and are capable of targeting, labeling, and manipulating diverse intracellular antigens. This study demonstrates an efficient and versatile intracellular protein delivery platform, especially for antibodies, and provides new possibilities for expanding protein-based therapeutics to intracellular "undruggable" targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Nano letters - 21(2021), 14 vom: 28. Juli, Seite 6022-6030 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Qun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody delivery |
|---|
| Anmerkungen: |
Date Completed 30.07.2021 Date Revised 30.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.nanolett.1c01190 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327738731 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327738731 | ||
| 003 | DE-627 | ||
| 005 | 20231225201441.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.nanolett.1c01190 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327738731 | ||
| 035 | |a (NLM)34227381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Qun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cytosolic Protein Delivery for Intracellular Antigen Targeting Using Supercharged Polypeptide Delivery Platform |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.07.2021 | ||
| 500 | |a Date Revised 30.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the well-recognized clinical success of therapeutic proteins, especially antibodies, their inability to penetrate the cell membrane restricts them to secretory extracellular or membrane-associated targets. Developing a direct cytosolic protein delivery system would offer unique opportunities for intracellular target-related therapeutic proteins. Here, we generated a supercharged polypeptide (SCP) with high cellular uptake efficiency, endosomal escape ability, and good biosafety and developed an SCP with an unnatural amino acid containing the phenylboronic acid (PBA) group, called PBA-SCP. PBA-SCP is capable of potently delivering proteins with various isoelectric points and molecular sizes into the cytosol of living cells without affecting their bioactivities. Importantly, cytosolically delivered antibodies remain functional and are capable of targeting, labeling, and manipulating diverse intracellular antigens. This study demonstrates an efficient and versatile intracellular protein delivery platform, especially for antibodies, and provides new possibilities for expanding protein-based therapeutics to intracellular "undruggable" targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antibody delivery | |
| 650 | 4 | |a cytosolic protein delivery | |
| 650 | 4 | |a intracellular targets | |
| 650 | 4 | |a phenylboronic acid | |
| 650 | 4 | |a supercharged polypeptide | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Proteins |2 NLM | |
| 700 | 1 | |a Yang, Yifan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dingkang |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Xiangdong |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Wenbing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nano letters |d 2001 |g 21(2021), 14 vom: 28. Juli, Seite 6022-6030 |w (DE-627)NLM154096849 |x 1530-6992 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:14 |g day:28 |g month:07 |g pages:6022-6030 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.nanolett.1c01190 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 14 |b 28 |c 07 |h 6022-6030 | ||